Cell Impact seeks shareholder approval to reduce share capital and secure broad authorization for future equity or convertible issuances to improve the company's financial flexibility.
Cell Impact has called an EGM for 8 December 2026 to reduce share capital from 66,348,284.60 kronor by up to 61,348,284.6 kronor to about 5,000,000 kronor without cancelling shares, and to authorise share/option/convertible issues without preferential rights. The issue authorisation creates a dilution overhang, while the capital reduction itself is not dilutive and no actual issuance terms are given. TO5 warrants can be exercised from 9 to 20 November 2026 and may affect the final capital.
They will vote on amendments to the articles of association, a reduction of share capital of up to 61,348,284.6 kronor to about 5,000,000 kronor without cancelling shares, and an authorisation for the board to issue shares, options and/or convertibles.
No. The article states the reduction shall be made without indragning av aktier, meaning no cancellation of shares.
Cell Impact AB has convened an extraordinary general meeting for December 8, 2026, to address its capital structure. The board proposes reducing share capital by up to 61.3 million kronor to approximately 5 million kronor without cancelling shares, alongside a request for authorization to issue new shares, options, or convertibles to enhance financial flexibility.
They will vote on amendments to the articles of association, a reduction of share capital of up to 61,348,284.6 kronor to about 5,000,000 kronor without cancelling shares, and an authorisation for the board to issue shares, options and/or convertibles.
No. The article states the reduction shall be made without indragning av aktier, meaning no cancellation of shares.